BRIEF-Loxo Oncology Initiates Rolling Submission Of NDA To U.S. FDA For TRK Fusion Cancers Treatment
December 20, 2017 at 07:47 AM EST
* LOXO ONCOLOGY INITIATES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR LAROTRECTINIB FOR THE TREATMENT OF TRK FUSION CANCERS